Shots:

• The positive opinion is based on P-III KEYNOTE-407 trials results assessing Keytruda + CT (carboplatin/paclitaxel/nab-paclitaxel) vs CT monothx. in patients with msq NSCLC
• The P-III KEYNOTE-407 trials resulted in improved OS & PFS and demonstrated rates of alopecia (47% vs 36%) and peripheral neuropathy (31% vs 25%)- were presented at ASCO 2018
• Keytruda (pembrolizumab) 100mg IV is a mAb- used as an anti-D-L1 therapy that blocks the interaction between PD-1 and its ligands i.e PD-L1 & PD- L2- further activating T lymphocytes. The CHMP opinion will be reviewed by EU for its futher approval- expected in H1’19

Ref: Merck | Image: Merck